And even though we have the power to protect against it, people are still needlessly suffering and dying. Sanofi attributed the timing to the World Health Organization and U.S. Food and Drug Administration delaying selection of vaccine virus strains to better match circulating strains of H3N2 viruses. This phenomenon, known as antigenic drift, has created a major roadblock in efforts to combat influenza.Thankfully, in partnership with global health authorities, scientists have developed yearly vaccines that help protect against the primary strains of the virus each season.
“Influenza is a serious threat, especially for older adults who are more vulnerable to serious complications and even death. In additional animal studies, both were shown to be well-tolerated when given in conjunction with either Flublok or Fluzone. This approval is the final step toward the company's complete transition to quadrivalent influenza vaccines in the U.S. Fluzone High-Dose Quadrivalent will be made available for immunization efforts during the 2020-2021 influenza season.

Influenza Virus Vaccine Trivalent Types A and B (Split Virion) Suspension for Injection Active Immunizing Agent for the Prevention of Influenza ATC Code: J07B B Manufactured by: Sanofi Pasteur Limited Toronto, Ontario, Canada Fabricated by: Sanofi Pasteur Inc. Swiftwater, PA 18370 USA Control #: 238651 Date of Approval: 28 April 2020 . strains of H3N2 viruses.The Academy and Centers for Disease Control and Prevention recommend everyone 6 months However, they do not protect against every strain, meaning yearly vaccination is required. Volunteers who received Fluzone earlier in the study will receive the current Fluzone vaccine, and volunteers who received Flublok will receive the current Flublok vaccine. to customers.Sanofi attributed the timing to the World Health Organization and U.S. Food and Drug Influenza is so underestimated that it seriously impacts the lives of millions, entire economies and society as a whole.Infographics on how we produce our influenza vaccines,a-look-inside-influenza-vaccines-today-and-tomorrow,Vaccines help prevent influenza and reduce the risks of its severe consequences,http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal,Click here for more information on cookies. An early-stage clinical trial is evaluating two licensed seasonal influenza vaccines, administered with or without novel adjuvants, for their safety and ability to generate an immune response. representative or call 1-800-VACCINE.Thank you for your interest in spreading the word on American Academy of Pediatrics.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail.


Flu is a contagious disease that spreads around the United States every year, usually between October and May.Anyone can get the flu, but it is more dangerous for some people. By continuing to browse this website, you agree to the use of such cookies.Click here for more information on cookies. Influenza Virus Vaccine Quadrivalent Types A and B (Split Virion) Suspension for Injection Active Immunizing Agent for the Prevention of Influenza ATC Code: J07B B Manufactured by: Sanofi Pasteur Limited Toronto, Ontario, Canada Fabricated by: Sanofi Pasteur Inc. Swiftwater, PA 18370 USA Control #: 238593 Date of Approval: 30 April 2020 . *Will be available in fall 2020, in time for the 2020-2021 flu season.FDA approval was based on data from a Phase 3 immunogenicity and safety study, in which Fluzone High-Dose Quadrivalent achieved the primary endpoint of non-inferior immunogenicity compared to two trivalent formulations of Fluzone High-Dose, each containing one of the two influenza B strains recommended for inclusion in the vaccine for the 2017-2018 influenza season.